AGMB

Sep 14, 2026, 20:05 UTC

Agomab Therapeutics announced positive Phase 1 results for AGMB-447 in idiopathic pulmonary fibrosis patients and submitted a CTA for the Phase 2 INSPIRIA study, which it intends to initiate before year-end.